(0.14%) 5 315.73 points
(0.20%) 39 989 points
(0.11%) 16 760 points
(0.65%) $79.14
(3.23%) $2.49
(-0.37%) $2 386.10
(0.59%) $29.91
(-0.31%) $1 066.80
(0.13%) $0.920
(0.29%) $10.70
(0.07%) $0.789
(0.16%) $90.83
Live Chart Being Loaded With Signals
Lumos Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for rare diseases. Its lead therapeutic candidate LUM-201 is an oral growth hormone secretagogue ibutamoren, which is in Phase 2 clinical trial for the treatment of pediatric growth hormone deficiency and other rare endocrine disorders...
Stats | |
---|---|
Today's Volume | 18 437.00 |
Average Volume | 29 791.00 |
Market Cap | 19.65M |
EPS | $0 ( 2024-05-15 ) |
Next earnings date | ( $-0.420 ) 2024-08-14 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -0.580 |
ATR14 | $0.0240 (0.99%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-01-04 | Pitukcheewanont Pisit Duke | Sell | 0 | Common Stock |
2023-06-01 | Pitukcheewanont Pisit Duke | Sell | 29 750 | Stock Option (Right to Buy) |
2024-02-01 | Pitukcheewanont Pisit Duke | Sell | 3 333 | Stock Option (Right to Buy) |
2024-07-01 | Pitukcheewanont Pisit Duke | Sell | 25 500 | Stock Option (Right to Buy) |
2023-08-01 | Mckew John C. | Sell | 1 593 | Common Stock |
INSIDER POWER |
---|
24.23 |
Last 99 transactions |
Buy: 596 623 | Sell: 145 033 |
Volume Correlation
Lumos Pharma Inc Correlation
10 Most Positive Correlations |
---|
10 Most Negative Correlations |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Lumos Pharma Inc Correlation - Currency/Commodity
Lumos Pharma Inc Financials
Annual | 2023 |
Revenue: | $2.05M |
Gross Profit: | $2.01M (97.85 %) |
EPS: | $-4.18 |
FY | 2023 |
Revenue: | $2.05M |
Gross Profit: | $2.01M (97.85 %) |
EPS: | $-4.18 |
FY | 2022 |
Revenue: | $1.52M |
Gross Profit: | $1.47M (96.78 %) |
EPS: | $-3.71 |
FY | 2021 |
Revenue: | $230.00 |
Gross Profit: | $0.00 (0.00 %) |
EPS: | $-0.00365 |
Financial Reports:
No articles found.
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Lumos Pharma Inc
Lumos Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for rare diseases. Its lead therapeutic candidate LUM-201 is an oral growth hormone secretagogue ibutamoren, which is in Phase 2 clinical trial for the treatment of pediatric growth hormone deficiency and other rare endocrine disorders. The company is headquartered in Austin, Texas.
About Live Signals
The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.
The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators